Xcout Intel
Coultreon Biopharma
Coultreon Biopharma is a clinical-stage biotechnology company headquartered in Leuven, Belgium, focused on developing next-generation precision medicines for immunology and autoimmune diseases. Backed by substantial venture funding, the company advances innovative therapies.
Subscribe to see Coultreon Biopharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Coultreon Biopharma at a glance
Coultreon Biopharma is a drug discovery company headquartered in Belgium. It has raised at least $125M across the 2 funding rounds on record, 1 of them with a disclosed amount. Its most recent funding round, Series A, raised $125M in April 2026. Xcout tracks 18 named people at Coultreon Biopharma, including Pierre Raboisson (Chief Executive Officer Chief Scientific Officer Co-founder).
Coultreon Biopharma leadership
- Pierre RaboissonChief Executive Officer Chief Scientific Officer Co-founder
- Guy PeetersChief Financial Officer Co-founder
- Marie De VulderChief Legal Officer Co-founder
- Nate MassariChief Business Officer
- Prista CharuwornChief Medical Officer
- Pieter PeetersOperating & Technology Officer Co-founder
12 more named people on record for Coultreon Biopharma, with roles, board committees and tenure — see the full roster →
Coultreon Biopharma funding rounds
At least $125M raised across the 2 rounds on record (1 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $125M | 10 named | |
| Seed | Undisclosed | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Coultreon Biopharma competitors
A few of Coultreon Biopharma's closest competitors — see the full list of competitors and alternatives →
COUR Pharmaceuticals is a clinical-stage biotechnology company headquartered in Evanston, Illinois, founded in 2015. The firm focuses on reprogramming the immune system to develop novel treatments for autoimmune diseases.
NXI Therapeutics AG is a biotech company based in Basel, Switzerland, focused on researching and developing selective immunosuppressive drugs and immunotherapies for autoimmune diseases and transplantation.
Promise Bio is a biotechnology research startup transforming immune-mediated disease treatment with advanced precision therapies. Headquartered in Tel Aviv, Israel, the company emerged from stealth following a seed investment.
Baseimmune is a biotechnology research company headquartered in London, United Kingdom, pioneering active immunotherapies. The company combines cutting-edge computational design with advanced protein engineering to develop next-generation vaccines.
Ahammune Biosciences is an India-based drug-discovery biotechnology company focused on developing small-molecule therapies for immune-mediated and inflammatory diseases. It serves pharmaceutical and healthcare markets by advancing novel immunomodulatory drug candidates toward clinical development.
Arkgen Bioscions is a South Korean immuno-oncology startup headquartered in Daejeon. The company recently raised a $6.67 million Series A funding round to advance its proprietary biotech research. It focuses on developing innovative biopharmaceutical treatments.
Get Coultreon Biopharma's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Coultreon Biopharma in Xcout Intel
- 18 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access